Company profile: Javelin Pharmaceuticals
1.1 - Company Overview
Company description
- Provider of specialty pharmaceutical research, development, and commercialization of products for the pain management market primarily in the United States and Europe, focusing on treatments for various pain disorders ranging from acute and episodic moderate-to-severe pain.
Products and services
- Cefadroxil: A cephalosporin-class antibiotic prescribed for skin diseases, urinary tract infections, and Pharyngitis and Tonsillitis, used in clinical settings to manage these specified bacterial conditions
- Ceftin: A cephalosporin-family antibiotic used to treat bacterial infections, applied in clinical therapy across infection presentations where cephalosporin treatment is indicated
- Chloramphenicol: A pharmaceutical-grade antibiotic used to treat bacterial infections, employed in clinical practice for medically appropriate antimicrobial treatment
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Javelin Pharmaceuticals
Disarm Therapeutics
HQ: United States
Website
- Description: Provider of disease-modifying therapeutics for patients with axonal degeneration, developing drugs that prevent axon loss and treat neurological diseases including multiple sclerosis, amyotrophic lateral sclerosis, glaucoma, and peripheral neuropathies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Disarm Therapeutics company profile →
Collegium Pharmaceutical
HQ: United States
Website
- Description: Provider of specialty pharmaceuticals for chronic pain, offering XTAMPZA ER (extended-release oxycodone for around-the-clock pain management), NUCYNTA ER (tapentadol for severe pain requiring daily, around-the-clock, long-term opioid treatment), NUCYNTA (tapentadol for moderate to severe acute pain in adults), BELBUCA (buprenorphine buccal film for long-term pain), and SYMPROIC (tablet for opioid-induced constipation in adults with chronic non-cancer pain).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Collegium Pharmaceutical company profile →
ReNeuron
HQ: United Kingdom
Website
- Description: Provider of stem cell-based exosome technologies and cell therapy programs. Offers the CustomEx platform for customizable exosomes delivering nucleic acids, proteins and gene editing; a conditionally immortalized iPSC platform for allogeneic cell lines and exosome production with specific tissue targeting; and hRPC for retinitis pigmentosa and CTX for stroke-induced disabilities, available for out-license outside of China.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ReNeuron company profile →
Xanodyne
HQ: United States
Website
- Description: Provider of integrated specialty pharmaceutical products, developing and commercializing offerings in women's healthcare and pain management in the United States.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Xanodyne company profile →
Gilgamesh Pharmaceuticals
HQ: United States
Website
- Description: Provider of novel psychotropic and psychedelic-inspired medicines for depression, bipolar depression, anxiety, stress-related disorders, and other conditions, developing compounds optimized for safety, tolerability, duration, and efficacy, including GM-1020 (oral, rapid-acting, non-dissociative NMDAR antagonist for potential at-home use), GM-2505 (short-acting 5-HT2A agonist), GM-5022 (non-hallucinogenic neuroplastogen), and GM-3009 (safer ibogaine analog for opioid use disorder, PTSD, and TBI).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Gilgamesh Pharmaceuticals company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Javelin Pharmaceuticals
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Javelin Pharmaceuticals
2.2 - Growth funds investing in similar companies to Javelin Pharmaceuticals
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Javelin Pharmaceuticals
4.2 - Public trading comparable groups for Javelin Pharmaceuticals
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →